RIPK2 and breast carcinoma: Hence, these results not only highlight that RIPK2 is a novel prognostic biomarker in breast cancer, but also suggest that targeting RIPK2 may improve the outcome of advanced breast cancer patients with RIPK2 amplification or overexpression.